Document:

Warrant for the purchase of shares of Series B Preferred Stock

 Exhibit 4.4 
  

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i)
EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL
AUTHORITIES. 
  
 RENOVIS, INC. 
  
 WARRANT TO PURCHASE 77,778 SHARES 
 OF SERIES B PREFERRED STOCK 
  
 THIS CERTIFIES THAT, for value received, GATX VENTURES, INC. and its assignees are entitled to subscribe for and purchase 77,778 shares of fully paid and
nonassessable Series B Preferred Stock (as adjusted pursuant to Section 4 hereof, the “Shares”) of RENOVIS, INC., a Delaware corporation (the “Company”), at the price of $1.80 per share (such price and such other price as shall
result, from time to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, (a) the term
“Series Preferred” shall mean the Company’s presently authorized Series B Preferred Stock, and any stock into or for which such Series B Preferred Stock may hereafter be converted or exchanged, and after the automatic conversion of
the Series B Preferred Stock to Common Stock shall mean the Company’s Common Stock, (b) the term “Date of Grant” shall mean April 27, 2001, (c) the term “Exercise Date” shall mean the date on which this Warrant is exercised,
and (d) the term “Other Warrants” shall mean any other warrants issued by the Company in connection with the transaction with respect to which this Warrant was issued, and any warrant issued upon transfer or partial exercise of or in lieu
of this Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly requires otherwise. 
  
 1. Term. The purchase right represented by this Warrant is exercisable, in whole or in part, at any time and from time to time from the Date of
Grant through the later of (i) ten (10) years after the Date of Grant or (ii) seven (7) years after the closing of the Company’s initial public offering of its Common Stock (“IPO”) effected pursuant to a Registration Statement on Form
S-1 (or its successor) filed under the Securities Act of 1933, as amended (the “Act”) (the “Term”). Upon request of the Company, the holder of this Warrant agrees to exercise the purchase right under this Warrant (including
without limitation by way of net issuance as provided in Section 10.2) contemporaneously with the closing of (a) a merger or consolidation in which the Company is not the surviving corporation, (b) the sale, lease, exchange, conveyance or other
disposition of all or substantially all of the assets of the Company or (c) the purchase by a person or group of related persons of all of the outstanding capital stock of the Company if (i) the Company receives solely cash in consideration for such
sale or merger, or (ii) (A) the acquiror in such sale or merger is publicly traded on any national securities exchange or the Nasdaq National Market and has a tangible 

 
net worth as of the end of its most recent fiscal year in excess of $200,000,000, (B) the net proceeds per share to the holder of this Warrant upon such
exercise will equal at least the product of the Warrant Price multiplied by three (3) and (C) all capital stock received as consideration for such sale or merger are registered pursuant to a registration statement filed under the Act. The Company
agrees to provide the holder of this Warrant not less than twenty (20) days’ prior written notice of the Company’s request that the holder exercise its purchase right hereunder in accordance with the provisions of Section 13 hereof.

  
 2. Method of Exercise; Payment; Issuance of New
Warrant. Subject to Section 1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof during the Term, in whole or in part and from time to time, at the election of the holder hereof, by (a) the surrender of
this Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer
to an account designated by the Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b) if in connection with a registered public offering of the
Company’s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of the Company; or (c) exercise of the “net issuance” right
provided for in Section 10.2 hereof. The person or persons in whose name(s) any certificate(s) representing shares of Series Preferred shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and
shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this Warrant is exercised,
except that, if the date of such surrender and payment (or giving such “net issuance” notice) is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the
close of business on the next suceeding date on which the stock transfer books are open. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be delivered to the holder as
soon as reasonably practicable but in any event within thirty (30) days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the Shares, if any, with respect to which this
Warrant shall not then have been exercised shall also be issued to the holder hereof within such thirty-day period; provided, however, at such time as the Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as
amended, if requested by the holder of this Warrant, the Company shall use its reasonable efforts to cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to a broker or other person (as
directed by the holder exercising this Warrant) within the time period required to settle any trade made by the holder after exercise of this Warrant. 
  
 3. Stock Fully Paid; Reservation of Shares. All Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon
issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issue thereof; provided, however, that holder shall be required to pay any and all taxes based upon
the net income of the holder. During the period within which the rights represented by 

  

 -2- 

 
this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its Series Preferred to provide for the exercise of the rights represented by this Warrant and a sufficient number of shares of its Common Stock to provide for the conversion of the Series
Preferred into Common Stock. If at any time during the Exercise Period the number of authorized but unissued shares of the Series Preferred or of its Common Stock shall not be sufficient o permit exercise of this Warrant, the Company will take such
corporate action as may, in the opinion of its counsel,be necessary to increase its authorized but unissued shares of Preferred Stoc and/or of its Common Stock to such number of shares as shall be sufficient for such purposes. 
  
 4. Adjustment of Warrant Price and Number of Shares. The number and
kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 
  
 (a) Reclassification or Merger. In case of any reclassification or change of securities of the class issuable upon
exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another
corporation (other than a merger with another corporation in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this
Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall (i) duly execute and deliver to the holder of this Warrant a new Warrant
as nearly equivalent as practicable to this Warrant (in form and substance reasonably satisfactory to the holder of this Warrant), or (ii) make appropriate provision without the issuance of a new Warrant, so that the holder of this Warrant shall
have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Series Preferred theretofore issuable upon
exercise of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, change, merger or sale by a holder of the number of shares of Series Preferred then purchasable under this
Warrant. Any new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4. The provisions of this subparagraph (a) shall similarly apply to successive
reclassifications, changes, mergers and transfers. 
  
 (b)
Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Series Preferred, the Warrant Price shall be proportionately decreased
and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in
the case of a combination. 
  
 (c) Stock Dividends and Other
Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall (i) pay a dividend with respect to Series Preferred 

  

 -3- 

 
payable in Series Preferred, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled to receive such
dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Series Preferred
outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Series Preferred outstanding immediately after such dividend or distribution; or (ii) prior to the occurrence of
an IPO, make any other distribution with respect to Series Preferred (except any distribution specifically provided for in Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant
shall receive upon exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Series Preferred (or Common Stock issuable upon conversion thereof) as of the record date fixed for the
determination of the shareholders of the Company entitled to receive such dividend or distribution. 
  
 (d) Adjustment of Number of Shares. Upon each adjustment in the Warrant Price, the number of Shares of Series Preferred purchasable hereunder shall
be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately
prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
  
 (e) Antidilution Rights. The other antidilution rights applicable to the Shares of Series Preferred purchasable hereunder are set forth in the
Company’s Certificate of Incorporation, as amended through the Date of Grant, a true and complete copy of which is attached hereto as Exhibit B (the “Charter”). Such antidilution rights shall not be restated, amended, modified or
waived in any manner without holder’s prior written consent if the effect of such restatement, amendment, modification or waiver on the holder hereof would be more adverse to the holder hereof than, and substantially dissimilar to, its effect
on the other holders of the Company’s Series Preferred. The Company shall promptly provide the holder hereof with any restatement, amendment, modification or waiver of the Charter promptly after the same has been made. 
  
 (f) No Duplicate Adjustments. Notwithstanding anything else to the
contrary contained herein, in no event will an adjustment be made under the provisions of this Section 4 to the number of Shares issuable upon exercise of this Warrant or the Warrant Price for any event if a corresponding adjustment having
substantially the same effect to the holder as any adjustment that otherwise would be made under the provisions of this Section 4 is made by the Company for any such event pursuant to the antidilution provisions of the Company’s Charter.

  
 5. Notice of Adjustments. Whenever the Warrant Price or
the number of Shares purchasable hereunder shall be adjusted pursuant to Section 4 hereof, the Company shall make a certificate signed by its chief financial officer or other officer designated by the Company setting forth, in reasonable detail, the
event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of
such 

  

 -4- 

 
certificate to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. In addition, whenever the
conversion price or conversion ratio of the Series Preferred shall be adjusted, the Company shall make a certificate signed by its chief financial officer or other officer designated by the Company setting forth, in reasonable detail, the event
requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the conversion price or ratio of the Series Preferred after giving effect to such adjustment, and shall cause copies of such certificate
to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. 
  
 6. Fractional Shares. No fractional shares of Series Preferred will be issued in connection with any exercise hereunder, but in lieu of such
fractional shares the Company shall make a cash payment therefor based on the fair market value of the Series Preferred on the date of exercise as reasonably determined in good faith by the Company’s Board of Directors. 
  
 7. Compliance with Act; Disposition of Warrant or Shares of Series
Preferred. 
  
 (a) Compliance with Act. The holder of
this Warrant, by acceptance hereof, agrees that this Warrant, and the shares of Series Preferred to be issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder does not
currently intend to and will not offer, sell or otherwise dispose of this Warrant, or any shares of Series Preferred to be issued upon exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not
result in a violation of the Act or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is
available, the holder hereof shall confirm in writing that the shares of Series Preferred so purchased (and any shares of Common Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or
resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company. This Warrant and all shares of Series Preferred issued upon exercise of this Warrant and all shares of Common Stock
issued upon conversion thereof (unless registered under the Act and any applicable state securities laws) shall be stamped or imprinted with any legends that may be reasonably required under state or federal law or deemed appropriate by counsel to
the Company, including but not limited to a legend in substantially the following form: 
  
 “THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION
STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES.”

  
 Said legend shall be removed by the Company, upon the request
of a holder, at such time as the restrictions on the transfer of the applicable security shall have terminated, and any other 

  

 -5- 

 
requirements or restrictions stated therein no longer apply. In addition, in connection with the issuance of this Warrant, the holder specifically represents
and warrants to the Company by acceptance of this Warrant as follows: 
  
 (1) The holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. To holder’s
knowledge, the Company has provided holder with all information requested by holder regarding the Company. The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection
with, any “distribution” thereof in violation of the Act. The holder also represents that the entire legal and beneficial interests of the Warrant and Shares the holder is acquiring is being acquired for, and will be held for, its account
only. 
  
 (2) The holder understands that this Warrant has not
been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder’s investment intent, and holder’s other representations and warranties, as
expressed herein. 
  
 (3) The holder further understands that
this Warrant must be held indefinitely unless subsequently registered under the Act and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of
the provisions of Rule 144, promulgated under the Act. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions in the forseeable future.

  
 (4) The holder is an “accredited investor” as such
term is defined in Rule 501 of Regulation D promulgated under the Act. 
  
 (b) Disposition of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any shares of Series Preferred acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or
shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if reasonably satisfactory to the Company,
to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or such shares of Series Preferred
or Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order
to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company, as promptly as practicable but no later than twenty (20) days after receipt of the written notice, shall
notify such holder that such holder may sell or otherwise dispose of this Warrant or such shares of Series Preferred or Common Stock, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant
to this Section 7(b) that the opinion of counsel for the holder or other evidence is not reasonably 

  

 -6- 

 
satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such determination has been made. Notwithstanding the
foregoing, this Warrant or such shares of Series Preferred or Common Stock may, as to such federal laws, be offered, sold or otherwise disposed of in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished
with such information, including an opinion of counsel, as the Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 or 144A have been satisfied. Each certificate representing this Warrant or the shares of
Series Preferred thus transferred (except a transfer pursuant to Rule 144) shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the
holder, such legend is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions. 
  
 (c) Applicability of Restrictions. Subject to compliance with
applicable federal and state securities laws, neither any restrictions of any legend described in this Warrant nor the requirements of Section 7(b) above shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Series
Preferred or Common Stock obtainable upon exercise thereof) or any part hereof (i) to a partner of the holder if the holder is a partnership or to a member of the holder if the holder is a limited liability company, (ii) to a partnership of which
the holder is a partner or to a limited liability company of which the holder is a member, or (iii) to any affiliate of the holder if the holder is a corporation; provided, however, in any such transfer, if applicable, the transferee
shall on the Company’s request agree in writing to be bound by the terms of this Warrant as if an original holder hereof. 
  
 8. Rights as Shareholders; Information. No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed the holder
of Series Preferred or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the
rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or
otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. Notwithstanding the foregoing, the Company will use commercially reasonable efforts to
transmit to the holder of this Warrant such information, documents and reports as are generally distributed to the holders of the Series Preferred (in their role as holders of the Series Preferred, excluding, by way of example, information,
documents and reports distributed to the holders of the Series Preferred in their role as officer or director of the Company) concurrently with the distribution thereof to the Series Preferred shareholders. In addition, as a condition to the
exercise of this Warrant, if all stockholders of the Series Preferred have entered into an agreement restricting the rights of such stockholders to transfer their Series Preferred, then the holder shall enter into the same such agreement or into an
agreement containing the same restrictions as those agreed to by all such stockholders, provided that the holder shall not be required to enter into such agreement or any similar agreement after the closing of the Company’s IPO. 
  

 -7- 

 9. Registration Rights. The Company grants registration rights to the holder of this Warrant for
any Common Stock of the Company obtained upon conversion of the Series Preferred, as set forth in that certain Investor Rights Agreement dated as of July 17, 2000, (as amended from time to time, the “Registration Rights Agreement”), with
the following exceptions and clarifications: 
  
 (1) The holder
will have no demand registration rights. 
  
 (2) The holder will
be subject to the same provisions regarding indemnification as contained in the Registration Rights Agreement. 
  
 (3) The registration rights are assignable by the holder of this Warrant in connection with a permitted transfer of this Warrant or the Shares.

  
 10. Additional Rights. 
  
 10.1 Acquisition and Financing Transactions. The Company shall provide
the holder of this Warrant with at least twenty (20) days’ written notice prior to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof): (i) the sale, lease, exchange,
conveyance or other disposition of all or substantially all of the Company’s property or business, or (ii) the Company’s merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any
transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of. 
  
 10.2 Right to Convert Warrant into Stock: Net Issuance. 
  
 (a) Right to Convert. In addition to and without limiting the rights
of the holder under the terms of this Warrant, if the fair market value of one share of the Series Preferred is greater than the Warrant Price (at the date of calculation as set forth below) the holder shall have the right to convert this Warrant or
any portion thereof (the “Conversion Right”) into shares of Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as provided in this Section 10.2 at any time or from time to time
during the Term. Upon exercise of the Conversion Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the holder (without payment by the holder of any
exercise price or any cash or other consideration) that number of shares of fully paid and nonassessable Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as is determined according to the
following formula: 
  

	          X =	  	 Y(A-B)

	  	A

  

	 Where: X =
	  	the number of shares of Series Preferred to be issued to holder under this Section 10.2

  

 -8- 

		
	 Y =
	  	the number of shares of Series Preferred purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being converted (at the
date of such calculation)
		
	 A =
	  	the fair market value of one share of Series Preferred (at the date of such calculation)
		
	 B =
	  	the Warrant Price (as adjusted to the date of such calculation)

  
 No fractional shares
shall be issuable upon exercise of the Conversion Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the
fair market value of the resulting fractional share on the Conversion Date (as hereinafter defined). For purposes of Section 10.2 of this Warrant, shares issued pursuant to the Conversion Right shall be treated as if they were issued upon the
exercise of this Warrant. 
  
 (b) Method of Exercise. The
Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of the Company together with a written statement (which may be in the form of Exhibit A-1 or Exhibit A-2 hereto) specifying that the holder
thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant which are being surrendered (referred to in Section 10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right.
Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written statement, or on such later date as is specified therein (the “Conversion Date”), and, at the election of the holder hereof,
may be made contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant to a Registration Statement under the Act (a “Public Offering”). Certificates for the shares issuable upon
exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30) days
following the Conversion Date. 
  
 (c) Determination of Fair
Market Value. For purposes of this Section 10.2, “fair market value” of a share of Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as of a particular date (the
“Determination Date”) shall mean: 
  
 (i) If the
Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company’s Registration Statement relating to such Public Offering (“Registration Statement”) has been declared effective by the
Securities and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with respect to such offering. 
  
 (ii) If the Conversion Right is not exercised in connection with and contingent upon a Public Offering, then as follows: 
  

 -9- 

 (A) If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be
the average of the closing prices of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the
Common Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; 
  
 (B) If traded on the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of
the closing bid prices of the Common Stock over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common Stock multiplied by the
number of shares of Common Stock into which each share of Series Preferred is then convertible; and 
  
 (C) If there is no public market for the Common Stock, then fair market value shall be determined by the Board of Directors of the Company in their good
faith judgment. 
  
 In making a determination under clauses (A) or (B) above, if
on the the Determination Date, five trading days had not passed since the IPO, then the fair market value of the Common Stock shall be the average closing prices or closing bid prices, as applicable, for the shorter period beginning on and including
the date of the IPO and ending on the trading day prior to to the Determination Date (or if such period includes only one trading day the closing price or closing bid price, as applicable, for such trading day). If closing prices or closing bid
prices are no longer reported by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other trading system at 4:00 p.m. New York City time on the
applicable trading day. 
  
 10.3 Exercise Prior to
Expiration. To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if the fair market value of one share of the Series Preferred is greater than the Warrant Price then in effect, this Warrant shall be
deemed automatically exercised pursuant to Section 10.2 above (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Series Preferred upon such expiration shall
be determined pursuant to Section 10.2(c). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any,
the holder hereof is to receive by reason of such automatic exercise. 
  
 10.4 Market Stand-Off Agreement. Holder shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common
Stock (or other securities) of the Company held by such holder (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one
hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Act; provided that: 
  

 -10- 

 (a) such agreement shall apply only to the Company’s first firm commitment underwritten public
offering of its Common Stock registered under the Act; and 
  
 (b)
all officers and directors of the Company and holders of at least five percent (5%) of the Company’s voting securities enter into similar agreements. 
  
 Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the
foregoing or which are necessary to give further effect thereto. The obligations described in this Section 10.4 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of
Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 10.4 and shall
have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
  
 11. Representations and Warranties. The Company represents and warrants to the holder of this Warrant as follows: 
  
 (a) This Warrant has been duly authorized and executed by the Company and is
a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing
specific performance, injunctive relief and other equitable remedies; 
  
 (b) The Shares have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued, fully paid and non-assessable; 
  
 (c) The rights, preferences, privileges and restrictions granted to or
imposed upon the Series Preferred and the holders thereof are as set forth in the Charter, and on the Date of Grant, each share of the Series Preferred represented by this Warrant is convertible into one share of Common Stock; 
  
 (d) The shares of Common Stock issuable upon conversion of the Shares have
been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and nonassessable; 
  
 (e) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in
accordance with the terms hereof will not be, inconsistent with the Company’s Charter or by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not
conflict with or contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other 

  

 -11- 

 
instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the registration or filing
with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings will be effected by the
time required thereby; 
  
 (f) There are no actions, suits,
audits, investigations or proceedings pending or, to the knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or authority which, if adversely determined, will have a material adverse
effect on the ability of the Company to perform its obligations under this Warrant; and 
  
 (g) The number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted basis (assuming the conversion of all outstanding convertible securities and the exercise of all outstanding
options and warrants), does not exceed 15,208,000 shares. 
  
 12.
Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 
  
 13. Notices. Any notice, request, communication or other document
required or permitted to be given or delivered to the holder hereof or the Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to
the Company at the address indicated therefor on the signature page of this Warrant. 
  
 14. Binding Effect on Successors. This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets, and
all of the obligations of the Company relating to the Series Preferred issuable upon the exercise or conversion of this Warrant shall survive the exercise, conversion and termination of this Warrant and all of the covenants and agreements of the
Company shall inure to the benefit of the successors and assigns of the holder hereof. 
  
 15. Lost Warrants or Stock Certificates. The Company covenants to the holder hereof that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or
stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 
  
 16. Descriptive Headings. The descriptive headings of the several paragraphs of this Warrant are inserted for
convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant. 
  

 -12- 

 17. Governing Law. This Warrant shall be construed and enforced in accordance with, and the rights
of the parties shall be governed by, the laws of the State of California. 
  
 18. Survival of Representations, Warranties and Agreements. All representations and warranties of the Company and the holder hereof contained herein shall survive the Date of Grant, the exercise or conversion
of this Warrant (or any part hereof) or the termination or expiration of rights hereunder. All agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer
operative. 
  
 19. Remedies. In case any one or more of the
covenants and agreements contained in this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and enforce their or its rights
either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant. The person
or entity alleging such breach shall give the breaching party written notice of such breach and a reasonable opportunity to cure the alleged breach, which cure period shall not extend beyond fifteen (15) days, except that there shall be no cure
period with respect to the following provisions of this Warrant: (i) the failure to comply with the last sentence of Section 1 of this Warrant, (ii) the failure to deliver pursuant to Section 2 of this Warrant, certificates for the shares of stock
purchased as a result of the exercise or conversion of this Warrant, (iii) the failure to comply with the second sentence of Section 7(b) of this Warrant, and (iv) the failure to comply with the notice provisions of Section 10.1 of this Warrant.

  
 20. No Impairment of Rights. The Company will not, by
amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times act in good faith in the carrying out of all such terms. 
  
 21. Severability. The invalidity or unenforceability of any provision
of this Warrant in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provisions of this Warrant, which shall remain in full force and effect. 
  
 22. Recovery of Litigation Costs. If any legal action or other
proceeding is brought for the enforcement of this Warrant, or because of an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be
entitled to recover reasonable attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which it or they may be entitled. 
  
 23. Entire Agreement; Modification. This Warrant constitutes the entire agreement between the parties pertaining to
the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with respect to such subject matter. 
  

 -13- 

 The Company has caused this Warrant to be duly executed and delivered as of the Date of Grant specified
above. 
  

	RENOVIS, INC.
		
	 By
	 	 /s/    Lynne
Zydowsky        

	 Title
	 	 President & COO

		
	 Address:
	 	 747 Fifty Second St.
 Oakland, CA 94609

  

 -14-Warrant for the purchase of shares of Series B Preferred Stock

 Exhibit 4.5 
  

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i)
EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL
AUTHORITIES. 
  
 RENOVIS, INC. 
  
 WARRANT TO PURCHASE 77,778 SHARES 
 OF SERIES B PREFERRED STOCK 
  
 THIS CERTIFIES THAT, for value received, TBCC FUNDING TRUST II and its assignees are entitled to subscribe for and purchase 77,778 shares of fully paid
and nonassessable Series B Preferred Stock (as adjusted pursuant to Section 4 hereof, the “Shares”) of RENOVIS, INC., a Delaware corporation (the “Company”), at the price of $1.80 per share (such price and such other price as
shall result, from time to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, (a) the
term “Series Preferred” shall mean the Company’s presently authorized Series B Preferred Stock, and any stock into or for which such Series B Preferred Stock may hereafter be converted or exchanged, and after the automatic conversion
of the Series B Preferred Stock to Common Stock shall mean the Company’s Common Stock, (b) the term “Date of Grant” shall mean April 27, 2001, (c) the term “Exercise Date” shall mean the date on which this Warrant is
exercised, and (d) the term “Other Warrants” shall mean any other warrants issued by the Company in connection with the transaction with respect to which this Warrant was issued, and any warrant issued upon transfer or partial exercise of
or in lieu of this Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly requires otherwise. 
  

1. Term. The purchase right represented by this Warrant is exercisable, in whole or in part, at any time and from time to time from the Date of
Grant through the later of (i) ten (10) years after the Date of Grant or (ii) seven (7) years after the closing of the Company’s initial public offering of its Common Stock (“IPO”) effected pursuant to a Registration Statement on Form
S-1 (or its successor) filed under the Securities Act of 1933, as amended (the “Act”) (the “Term”). Upon request of the Company, the holder of this Warrant agrees to exercise the purchase right under this Warrant (including
without limitation by way of net issuance as provided in Section 10.2) contemporaneously with the closing of (a) a merger or consolidation in which the Company is not the surviving corporation, (b) the sale, lease, exchange, conveyance or other
disposition of all or substantially all of the assets of the Company or (c) the purchase by a person or group of related persons of all of the outstanding capital stock of the Company if (i) the Company receives solely cash in consideration for such
sale or merger, or (ii) (A) the acquiror in such sale or merger is publicly traded on any national securities exchange or the Nasdaq National Market and has a tangible 

 
net worth as of the end of its most recent fiscal year in excess of $200,000,000, (B) the net proceeds per share to the holder of this Warrant upon such
exercise will equal at least the product of the Warrant Price multiplied by three (3) and (C) all capital stock received as consideration for such sale or merger are registered pursuant to a registration statement filed under the Act. The Company
agrees to provide the holder of this Warrant not less than twenty (20) days’ prior written notice of the Company’s request that the holder exercise its purchase right hereunder in accordance with the provisions of Section 13 hereof.

  
 2. Method of Exercise; Payment; Issuance of New
Warrant. Subject to Section 1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof during the Term, in whole or in part and from time to time, at the election of the holder hereof, by (a) the surrender of
this Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer
to an account designated by the Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b) if in connection with a registered public offering of the
Company’s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of the Company; or (c) exercise of the “net issuance” right
provided for in Section 10.2 hereof. The person or persons in whose name(s) any certificate(s) representing shares of Series Preferred shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and
shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this Warrant is exercised,
except that, if the date of such surrender and payment (or giving such “net issuance” notice) is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the
close of business on the next suceeding date on which the stock transfer books are open. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be delivered to the holder as
soon as reasonably practicable but in any event within thirty (30) days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the Shares, if any, with respect to which this
Warrant shall not then have been exercised shall also be issued to the holder hereof within such thirty-day period; provided, however, at such time as the Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as
amended, if requested by the holder of this Warrant, the Company shall use its reasonable efforts to cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to a broker or other person (as
directed by the holder exercising this Warrant) within the time period required to settle any trade made by the holder after exercise of this Warrant. 
  
 3. Stock Fully Paid; Reservation of Shares. All Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon
issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issue thereof; provided, however, that holder shall be required to pay any and all taxes based upon
the net income of the holder. During the period within which the rights represented by 

  

 -2- 

 
this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its Series Preferred to provide for the exercise of the rights represented by this Warrant and a sufficient number of shares of its Common Stock to provide for the conversion of the Series
Preferred into Common Stock. If at any time during the Exercise Period the number of authorized but unissued shares of the Series Preferred or of its Common Stock shall not be sufficient o permit exercise of this Warrant, the Company will take such
corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Preferred Stoc and/or of its Common Stock to such number of shares as shall be sufficient for such purposes. 
  
 4. Adjustment of Warrant Price and Number of Shares. The number and
kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 
  
 (a) Reclassification or Merger. In case of any reclassification or change of securities of the class issuable upon
exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another
corporation (other than a merger with another corporation in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this
Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall (i) duly execute and deliver to the holder of this Warrant a new Warrant
as nearly equivalent as practicable to this Warrant (in form and substance reasonably satisfactory to the holder of this Warrant), or (ii) make appropriate provision without the issuance of a new Warrant, so that the holder of this Warrant shall
have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Series Preferred theretofore issuable upon
exercise of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, change, merger or sale by a holder of the number of shares of Series Preferred then purchasable under this
Warrant. Any new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4. The provisions of this subparagraph (a) shall similarly apply to successive
reclassifications, changes, mergers and transfers. 
  
 (b)
Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Series Preferred, the Warrant Price shall be proportionately decreased
and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in
the case of a combination. 
  
 (c) Stock Dividends and Other
Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall (i) pay a dividend with respect to Series Preferred 

  

 -3- 

 
payable in Series Preferred, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled to receive such
dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Series Preferred
outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Series Preferred outstanding immediately after such dividend or distribution; or (ii) prior to the occurrence of
an IPO, make any other distribution with respect to Series Preferred (except any distribution specifically provided for in Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant
shall receive upon exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Series Preferred (or Common Stock issuable upon conversion thereof) as of the record date fixed for the
determination of the shareholders of the Company entitled to receive such dividend or distribution. 
  
 (d) Adjustment of Number of Shares. Upon each adjustment in the Warrant Price, the number of Shares of Series Preferred purchasable hereunder shall
be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately
prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
  
 (e) Antidilution Rights. The other antidilution rights applicable to the Shares of Series Preferred purchasable hereunder are set forth in the
Company’s Certificate of Incorporation, as amended through the Date of Grant, a true and complete copy of which is attached hereto as Exhibit B (the “Charter”). Such antidilution rights shall not be restated, amended, modified or
waived in any manner without holder’s prior written consent if the effect of such restatement, amendment, modification or waiver on the holder hereof would be more adverse to the holder hereof than, and substantially dissimilar to, its effect
on the other holders of the Company’s Series Preferred. The Company shall promptly provide the holder hereof with any restatement, amendment, modification or waiver of the Charter promptly after the same has been made. 
  
 (f) No Duplicate Adjustments. Notwithstanding anything else to the
contrary contained herein, in no event will an adjustment be made under the provisions of this Section 4 to the number of Shares issuable upon exercise of this Warrant or the Warrant Price for any event if a corresponding adjustment having
substantially the same effect to the holder as any adjustment that otherwise would be made under the provisions of this Section 4 is made by the Company for any such event pursuant to the antidilution provisions of the Company’s Charter.

  
 5. Notice of Adjustments. Whenever the Warrant Price or
the number of Shares purchasable hereunder shall be adjusted pursuant to Section 4 hereof, the Company shall make a certificate signed by its chief financial officer or other officer designated by the Company setting forth, in reasonable detail, the
event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of
such 

  

 -4- 

 
certificate to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. In addition, whenever the
conversion price or conversion ratio of the Series Preferred shall be adjusted, the Company shall make a certificate signed by its chief financial officer or other officer designated by the Company setting forth, in reasonable detail, the event
requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the conversion price or ratio of the Series Preferred after giving effect to such adjustment, and shall cause copies of such certificate
to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. 
  
 6. Fractional Shares. No fractional shares of Series Preferred will be issued in connection with any exercise hereunder, but in lieu of such
fractional shares the Company shall make a cash payment therefor based on the fair market value of the Series Preferred on the date of exercise as reasonably determined in good faith by the Company’s Board of Directors. 
  
 7. Compliance with Act; Disposition of Warrant or Shares of Series
Preferred. 
  
 (a) Compliance with Act. The holder of
this Warrant, by acceptance hereof, agrees that this Warrant, and the shares of Series Preferred to be issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder does not
currently intend to and will not offer, sell or otherwise dispose of this Warrant, or any shares of Series Preferred to be issued upon exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not
result in a violation of the Act or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is
available, the holder hereof shall confirm in writing that the shares of Series Preferred so purchased (and any shares of Common Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or
resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company. This Warrant and all shares of Series Preferred issued upon exercise of this Warrant and all shares of Common Stock
issued upon conversion thereof (unless registered under the Act and any applicable state securities laws) shall be stamped or imprinted with any legends that may be reasonably required under state or federal law or deemed appropriate by counsel to
the Company, including but not limited to a legend in substantially the following form: 
  
 “THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION
STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES.”

  
 Said legend shall be removed by the Company, upon the request
of a holder, at such time as the restrictions on the transfer of the applicable security shall have terminated, and any other 

  

 -5- 

 
requirements or restrictions stated therein no longer apply. In addition, in connection with the issuance of this Warrant, the holder specifically represents
and warrants to the Company by acceptance of this Warrant as follows: 
  
 (1) The holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. To holder’s
knowledge, the Company has provided holder with all information requested by holder regarding the Company. The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection
with, any “distribution” thereof in violation of the Act. The holder also represents that the entire legal and beneficial interests of the Warrant and Shares the holder is acquiring is being acquired for, and will be held for, its account
only. 
  
 (2) The holder understands that this Warrant has not
been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder’s investment intent, and holder’s other representations and warranties, as
expressed herein. 
  
 (3) The holder further understands that
this Warrant must be held indefinitely unless subsequently registered under the Act and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of
the provisions of Rule 144, promulgated under the Act. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions in the forseeable future.

  
 (4) The holder is an “accredited investor” as such
term is defined in Rule 501 of Regulation D promulgated under the Act. 
  
 (b) Disposition of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any shares of Series Preferred acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or
shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if reasonably satisfactory to the Company,
to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or such shares of Series Preferred
or Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order
to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company, as promptly as practicable but no later than twenty (20) days after receipt of the written notice, shall
notify such holder that such holder may sell or otherwise dispose of this Warrant or such shares of Series Preferred or Common Stock, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant
to this Section 7(b) that the opinion of counsel for the holder or other evidence is not reasonably 

  

 -6- 

 
satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such determination has been made. Notwithstanding the
foregoing, this Warrant or such shares of Series Preferred or Common Stock may, as to such federal laws, be offered, sold or otherwise disposed of in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished
with such information, including an opinion of counsel, as the Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 or 144A have been satisfied. Each certificate representing this Warrant or the shares of
Series Preferred thus transferred (except a transfer pursuant to Rule 144) shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the
holder, such legend is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions. 
  
 (c) Applicability of Restrictions. Subject to compliance with
applicable federal and state securities laws, neither any restrictions of any legend described in this Warrant nor the requirements of Section 7(b) above shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Series
Preferred or Common Stock obtainable upon exercise thereof) or any part hereof (i) to a partner of the holder if the holder is a partnership or to a member of the holder if the holder is a limited liability company, (ii) to a partnership of which
the holder is a partner or to a limited liability company of which the holder is a member, or (iii) to any affiliate of the holder if the holder is a corporation; provided, however, in any such transfer, if applicable, the transferee
shall on the Company’s request agree in writing to be bound by the terms of this Warrant as if an original holder hereof. 
  
 8. Rights as Shareholders; Information. No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed the holder
of Series Preferred or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the
rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or
otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. Notwithstanding the foregoing, the Company will use commercially reasonable efforts to
transmit to the holder of this Warrant such information, documents and reports as are generally distributed to the holders of the Series Preferred (in their role as holders of the Series Preferred, excluding, by way of example, information,
documents and reports distributed to the holders of the Series Preferred in their role as officer or director of the Company) concurrently with the distribution thereof to the Series Preferred shareholders. In addition, as a condition to the
exercise of this Warrant, if all stockholders of the Series Preferred have entered into an agreement restricting the rights of such stockholders to transfer their Series Preferred, then the holder shall enter into the same such agreement or into an
agreement containing the same restrictions as those agreed to by all such stockholders, provided that the holder shall not be required to enter into such agreement or any similar agreement after the closing of the Company’s IPO. 
  

 -7- 

 9. Registration Rights. The Company grants registration rights to the holder of this Warrant for
any Common Stock of the Company obtained upon conversion of the Series Preferred, as set forth in that certain Investor Rights Agreement dated as of July 17, 2000, (as amended from time to time, the “Registration Rights Agreement”), with
the following exceptions and clarifications: 
  
 (1) The holder
will have no demand registration rights. 
  
 (2) The holder will
be subject to the same provisions regarding indemnification as contained in the Registration Rights Agreement. 
  
 (3) The registration rights are assignable by the holder of this Warrant in connection with a permitted transfer of this Warrant or the Shares.

  
 10. Additional Rights. 
  
 10.1 Acquisition and Financing Transactions. The Company shall
provide the holder of this Warrant with at least twenty (20) days’ written notice prior to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof): (i) the sale, lease,
exchange, conveyance or other disposition of all or substantially all of the Company’s property or business, or (ii) the Company’s merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the
Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of. 
  
 10.2 Right to Convert Warrant into Stock: Net Issuance. 
  
 (a) Right to Convert. In addition to and without limiting the rights
of the holder under the terms of this Warrant, if the fair market value of one share of the Series Preferred is greater than the Warrant Price (at the date of calculation as set forth below) the holder shall have the right to convert this Warrant or
any portion thereof (the “Conversion Right”) into shares of Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as provided in this Section 10.2 at any time or from time to time
during the Term. Upon exercise of the Conversion Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the holder (without payment by the holder of any
exercise price or any cash or other consideration) that number of shares of fully paid and nonassessable Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as is determined according to the
following formula: 
  

	 X  =
	 	   Y(A-B)

	 	 	       A

  

	 Where:  X  =
	  	the number of shares of Series Preferred to be issued to holder under this Section 10.2

  

 -8- 

	             Y  =
	  	the number of shares of Series Preferred purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being converted (at the
date of such calculation)
		
	             A  =
	  	the fair market value of one share of Series Preferred (at the date of such calculation)
		
	             B  =
	  	the Warrant Price (as adjusted to the date of such calculation)

  
 No fractional shares
shall be issuable upon exercise of the Conversion Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the
fair market value of the resulting fractional share on the Conversion Date (as hereinafter defined). For purposes of Section 10.2 of this Warrant, shares issued pursuant to the Conversion Right shall be treated as if they were issued upon the
exercise of this Warrant. 
  
 (b) Method of Exercise. The
Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of the Company together with a written statement (which may be in the form of Exhibit A-l or Exhibit A-2 hereto) specifying that the holder
thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant which are being surrendered (referred to in Section 10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right.
Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written statement, or on such later date as is specified therein (the “Conversion Date”), and, at the election of the holder hereof,
may be made contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant to a Registration Statement under the Act (a “Public Offering”). Certificates for the shares issuable upon
exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30) days
following the Conversion Date. 
  
 (c) Determination of Fair
Market Value. For purposes of this Section 10.2, “fair market value” of a share of Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as of a particular date (the
“Determination Date”) shall mean: 
  
 (i) If the
Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company’s Registration Statement relating to such Public Offering (“Registration Statement”) has been declared effective by the
Securities and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with respect to such offering. 
  
 (ii) If the Conversion Right is not exercised in connection with and contingent upon a Public Offering, then as follows: 
  

 -9- 

 (A) If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be
the average of the closing prices of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the
Common Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; 
  
 (B) If traded on the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of
the closing bid prices of the Common Stock over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common Stock multiplied by the
number of shares of Common Stock into which each share of Series Preferred is then convertible; and 
  
 (C) If there is no public market for the Common Stock, then fair market value shall be determined by the Board of Directors of the Company in their good
faith judgment. 
  
 In making a determination under clauses (A) or (B) above, if
on the the Determination Date, five trading days had not passed since the IPO, then the fair market value of the Common Stock shall be the average closing prices or closing bid prices, as applicable, for the shorter period beginning on and including
the date of the IPO and ending on the trading day prior to to the Determination Date (or if such period includes only one trading day the closing price or closing bid price, as applicable, for such trading day). If closing prices or closing bid
prices are no longer reported by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other trading system at 4:00 p.m. New York City time on the
applicable trading day. 
  
 10.3 Exercise Prior to
Expiration. To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if the fair market value of one share of the Series Preferred is greater than the Warrant Price then in effect, this Warrant shall be
deemed automatically exercised pursuant to Section 10.2 above (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Series Preferred upon such expiration shall
be determined pursuant to Section 10.2(c). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any,
the holder hereof is to receive by reason of such automatic exercise. 
  
 10.4 Market Stand-Off Agreement. Holder shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common
Stock (or other securities) of the Company held by such holder (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one
hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Act; provided that: 
  

 -10- 

 (a) such agreement shall apply only to the Company’s first firm commitment underwritten public
offering of its Common Stock registered under the Act; and 
  
 (b)
all officers and directors of the Company and holders of at least five percent (5%) of the Company’s voting securities enter into similar agreements. 
  
 Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the
foregoing or which are necessary to give further effect thereto. The obligations described in this Section 10.4 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of
Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 10.4 and shall
have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
  
 11. Representations and Warranties. The Company represents and warrants to the holder of this Warrant as follows: 
  
 (a) This Warrant has been duly authorized and executed by the Company and is
a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing
specific performance, injunctive relief and other equitable remedies; 
  
 (b) The Shares have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued, fully paid and non-assessable; 
  
 (c) The rights, preferences, privileges and restrictions granted to or
imposed upon the Series Preferred and the holders thereof are as set forth in the Charter, and on the Date of Grant, each share of the Series Preferred represented by this Warrant is convertible into one share of Common Stock; 
  
 (d) The shares of Common Stock issuable upon conversion of the Shares have
been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and nonassessable; 
  
 (e) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in
accordance with the terms hereof will not be, inconsistent with the Company’s Charter or by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not
conflict with or contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other 

  

 -11- 

 
instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the registration or filing
with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings will be effected by the
time required thereby; 
  
 (f) There are no actions, suits,
audits, investigations or proceedings pending or, to the knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or authority which, if adversely determined, will have a material adverse
effect on the ability of the Company to perform its obligations under this Warrant; and 
  
 (g) The number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted basis (assuming the conversion of all outstanding convertible securities and the exercise of all outstanding
options and warrants), does not exceed 15,208,000 shares. 
  
 12.
Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 
  
 13. Notices. Any notice, request, communication or other document
required or permitted to be given or delivered to the holder hereof or the Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to
the Company at the address indicated therefor on the signature page of this Warrant. 
  
 14. Binding Effect on Successors. This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets, and
all of the obligations of the Company relating to the Series Preferred issuable upon the exercise or conversion of this Warrant shall survive the exercise, conversion and termination of this Warrant and all of the covenants and agreements of the
Company shall inure to the benefit of the successors and assigns of the holder hereof. 
  
 15. Lost Warrants or Stock Certificates. The Company covenants to the holder hereof that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant
or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 
  
 16. Descriptive Headings. The descriptive headings of the several
paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant. 
  

 -12- 

 17. Governing Law. This Warrant shall be construed and enforced in accordance with, and the rights
of the parties shall be governed by, the laws of the State of California. 
  
 18. Survival of Representations, Warranties and Agreements. All representations and warranties of the Company and the holder hereof contained herein shall survive the Date of Grant, the exercise or conversion
of this Warrant (or any part hereof) or the termination or expiration of rights hereunder. All agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer
operative. 
  
 19. Remedies. In case any one or more of the
covenants and agreements contained in this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and enforce their or its rights
either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant. The person
or entity alleging such breach shall give the breaching party written notice of such breach and a reasonable opportunity to cure the alleged breach, which cure period shall not extend beyond fifteen (15) days, except that there shall be no cure
period with respect to the following provisions of this Warrant: (i) the failure to comply with the last sentence of Section 1 of this Warrant, (ii) the failure to deliver pursuant to Section 2 of this Warrant, certificates for the shares of stock
purchased as a result of the exercise or conversion of this Warrant, (iii) the failure to comply with the second sentence of Section 7(b) of this Warrant, and (iv) the failure to comply with the notice provisions of Section 10.1 of this Warrant.

  
 20. No Impairment of Rights. The Company will not, by
amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times act in good faith in the carrying out of all such terms. 
  
 21. Severability. The invalidity or unenforceability of any provision
of this Warrant in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provisions of this Warrant, which shall remain in full force and effect. 
  
 22. Recovery of Litigation Costs. If any legal action or other
proceeding is brought for the enforcement of this Warrant, or because of an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be
entitled to recover reasonable attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which it or they may be entitled. 
  
 23. Entire Agreement; Modification. This Warrant constitutes the entire agreement between the parties pertaining to
the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with respect to such subject matter. 
  

 -13- 

 The Company has caused this Warrant to be duly executed and delivered as of the Date of Grant specified
above. 
  

	RENOVIS, INC.
		
	 By
	 	 /s/    Lynne Zydowsky

	 Title
	 	 President & COO

		
	 Address:
	 	        747 Fifty Second St.
	 	 	        Oakland, CA 94609

  

 -14-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]